Results 11 to 20 of about 24,724 (196)

Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm. [PDF]

Cancer
Abstract Background In younger, fit patients with acute myeloid leukemia (AML), intensive chemotherapy (IC) followed by consolidation or allogeneic hematopoietic stem cell transplantation (HSCT) is the standard approach. The authors performed a systematic review and meta‐analysis to evaluate younger patients with AML treated with hypomethylating agents
Perrone S, De Fazio L, Monachetti S, Molica M.   +3 more
europepmc   +2 more sources

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma

Cancer Medicine, 2023
Background There is an urgent need for effective treatment of patients with relapsed/refractory diffuse large B‐cell lymphoma (R/R‐DLBCL). This trial investigated the efficacy of decitabine in combination with rituximab, cisplatin, cytarabine ...
Xiaoshuang Kong, Xudong Zhang, Mengjie Ding, Xiaoyan Feng, Meng Dong, Lei Zhang, Xiaorui Fu, Ling Li, Xin Li, Zhenchang Sun, Jiaqin Yan, Xinhua Wang, Xiaolong Wu, Qingjiang Chen, Mingzhi Zhang, Linan Zhu   +15 more
doaj   +1 more source

Abnormal Ferroptosis in Myelodysplastic Syndrome

Frontiers in Oncology, 2020
BackgroundFerroptosis is a form of iron-dependent non-apoptotic cell death, with characteristics of loss of the activity of the lipid repair enzyme, glutathione (GSH) peroxidase 4 (GPX4), and accumulation of lethal reactive lipid oxygen species.
Qi Lv, Haiyue Niu, Lanzhu Yue, Jiaxi Liu, Liyan Yang, Chunyan Liu, Huijuan Jiang, Shuwen Dong, Zonghong Shao, Limin Xing, Huaquan Wang   +10 more
doaj   +1 more source

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

Journal for ImmunoTherapy of Cancer, 2021
Background Programmed death-1 (PD-1) blockade monotherapy induced durable remission in a subset of patients with relapsed/refractory classical Hodgkin lymphoma (cHL). We asked whether the anti-PD-1 agent, camrelizumab, combined with the DNA demethylating
Weidong Han, Malcolm Brock, Chunmeng Wang, Liang Dong, Qingming Yang, Meixia Chen, Fengxia Shi, Jiejie Liu   +7 more
doaj   +1 more source

Decitabine Promotes Modulation in Phenotype and Function of Monocytes and Macrophages That Drive Immune Response Regulation

Cells, 2021
Decitabine is an approved hypomethylating agent used for treating hematological malignancies. Although decitabine targets altered cells, epidrugs can trigger immunomodulatory effects, reinforcing the hypothesis of immunoregulation in treated patients. We
Fabiana Albani Zambuzi, Priscilla Mariane Cardoso-Silva, Ricardo Cardoso Castro, Caroline Fontanari, Flavio da Silva Emery, Fabiani Gai Frantz   +5 more
doaj   +1 more source

Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. [PDF]

, 2014
BackgroundIn 31 solid tumor patients treated with the demethylating agent decitabine, we performed tumor biopsies before and after the first cycle of decitabine and used immunohistochemistry (IHC) to assess whether decitabine increased expression of ...
A Kumari, AS Yang, C Festuccia, C Zeller, CA Stidley, CJ Piyathilake, D Ma, D Matei, D Shang, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DW Shen, E Gordian, E San Jose-Eneriz, EA Braga, F Crea, F Fang, H Iwata, H Kantarjian, H Kroeger, HM Kantarjian, J Charlet, J Shia, JA Plumb, JP Issa, JP Issa, JS Kim, K Ghoshal, K Onda, K Ramachandran, K Tikoo, KY Tse, L Ding, L Rothem, MA Kane, ML Orta, NH Nabilsi, R Zhao, RH Finnell, S Fu, S Vijayaraghavalu, SB Baylin, SS Muerkoster, T Tanaka, TB Lee, VF Chekhun, X Chang, XJ Liang, Y Li, Y Oki, Y Zhang, ZG Liu   +55 more
core   +2 more sources

Therapeutic effect of folic acid combined with decitabine on diabetic mice [PDF]

International Journal of Ophthalmology, 2023
AIM: To evaluate the therapeutic effect of folic acid combined with decitabine on diabetic mice. METHODS: The diabetic model of db/db mice were randomly divided into model group, folic acid group, decitabine group, folic acid combined with decitabine ...
Gang Du, Yong Yan, Jun-Feng Gao, Chun-Yan Guo, Xiao Shen, Xun-Wen Lei   +5 more
doaj   +1 more source

Blastic plasmacytoid dendritic cell neoplasm: Genomics mark epigenetic dysregulation as a primary therapeutic target [PDF]

, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy for which there is still no effective B therapy.
Abate F., Agostinelli C., Amente S., Berti E., Bertolini F., Brundu F., Cerroni L., Dellino G. I., Etebari M., Facchetti F., Falini B., Fuligni F., Indio V., Laginestra M. A., Melle F., Motta G., Orecchioni S., Paulli M., Piccioni R., Pileri A., Pileri S. A., Pimpinelli N., Rabadan R., Rossi M., Sabattini E., Sapienza M. R., Tabanelli V., Talarico G., Tarantino G., Tripodo C., Truni M.   +30 more
core   +2 more sources

Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study

Hematology, 2023
Objective Anthracyclines and cytarabine have comprised standard induction therapy for acute myeloid leukemia (AML) for decades. Low overall survival of AML is due to non-remission or relapse after remission.
Zhibo Guo, Dan Guo, Desheng Kong, Sicheng Bian, Leilei Lin, Shengjin Fan, Qi Li, Yanqiu Zhao, Yanmeng Jiang, Jiangrong Yan, Zheren Wang, Lili Sun, Yinghua Li   +12 more
doaj   +1 more source

Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine

Endocrine Oncology, 2023
Downregulation of tumor suppression genes by DNA hypermethylation has been proposed as a potential cause of neuroendocrine neoplasm (NEN) formation. In this report, we present a patient simultaneously diagnosed with acute myeloid leukemia (AML) and a ...
Syed Ehsanullah, Nikolaos A Trikalinos
doaj   +1 more source